Evidence map›Paper›PMID 41449577›Full record

ArticleAnnals of clinical and translational neurology2026

Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia.

Christopher H Gibbons, Todd Levine, Charles H Adler, Bailey Bellaire, Ningshan Wang, Pinky Agarwal, Georgina M Aldridge, Alexandru Barboi, Daniel Claassen, Virgilio G H Evidente and 22 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04700722 (Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04700722 completednot on this map

Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy

TypeobservationalSponsorCND Life SciencesRan2021 to 2023Enrolled428ConditionsParkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic FailureArmsSkin Biopsy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Christopher H GibbonsDepartment of Neurology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-0087-5336
Todd LevineHonorhealth Neurology, Scottsdale, Arizona, USA.
Charles H AdlerDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Bailey BellaireCND Life Sciences, Scottsdale, Arizona, USA.
Ningshan WangDepartment of Neurology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Pinky AgarwalBooth Gardner Parkinson's Center, Evergreen Health, Kirkland, Washington, USA.
Georgina M AldridgeDepartment of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Alexandru BarboiDepartment of Neurology, Northshore University Health System, Evanston, Illinois, USA.
Daniel ClaassenDepartment of Neurology, Vanderbilt, Nashville, Tennessee, USA.ORCID 0000-0002-9853-4902
Virgilio G H EvidenteMovement Disorder Center of Arizona, Scottsdale, Arizona, USA.
Douglas GalaskoDepartment of Neurology, University of California, San Diego, La Jolla, California, USA.
Alejandra Gonzalez-DuarteDepartment of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
Ramon GilParkinson's Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, USA.
Mark GudesblattDepartment of Neurology, New York University Grossman Long Island School of Medicine, Mineola, New York, USA.
Stuart H IsaacsonParkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA.
Horacio KaufmannDepartment of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
Pravin KhemaniDepartment of Neurology, Swedish Medical Center, Seattle, Washington, USA.
Rajeev KumarRocky Mountain Movement Disorders Center, Englewood, Colorado, USA.
Guillaume LamotteDepartment of Neurology, University of Utah, Salt Lake City, Utah, USA.
Andy J LiuDepartment of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
Nikolaus R McFarlandDepartment of Neurology, University of Florida Health Center, Gainesville, Florida, USA.
Mitchell G MiglisDepartment of Neurology, Stanford University Medical Center, Stanford, California, USA.ORCID 0000-0001-8488-0313
Adam ReynoldsTuscan Center for Neurosciences, Tucson, Arizona, USA.
Gregory A SahagianThe Neurology Center of Southern California, San Diego, California, USA.
Marie-Helene Saint-HilaireDepartment of Neurology, Boston Medical Center, Boston, Massachusetts, USA.
Julie B SchwartzbardAventura Associates, Miami, Florida, USA.
Wolfgang SingerDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-1263-6850
Michael J SoileauTexas Movement Disorder Specialists, Georgetown, Texas, USA.ORCID 0000-0002-3944-1327
Steven VerninoDepartment of Neurology, University of Texas Southwestern, Dallas, Texas, USA.ORCID 0000-0001-7799-8495
Patricio Millar VernettiDepartment of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
Oleg YersteinDepartment of Neurology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Roy FreemanDepartment of Neurology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-3976-6022

Funding

NIH HHS NIH R44NS117214
6 · The paper itself

Abstract

objectiveTo determine the test performance of cutaneous phosphorylated alpha-synuclein (P-SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls.

methodsThis is the first subgroup analysis of the Synuclein-One study, a prospective, blinded study evaluating P-SYN detection from skin biopsies in 218 subjects with a referral diagnosis of control (N = 151) and DLB (N = 67). All subjects completed detailed examinations, questionnaires, and had skin biopsies for detection of P-SYN. DLB patients were included if meeting the 4th DLB consensus probable criteria. Control subjects, aged 40-99, had no history, examination findings, or symptoms suggestive of a synucleinopathy or neurodegenerative disease. An expert review panel, blinded to pathological data, determined the final diagnosis. Controls with reduced MoCA (MoCA < 26, N = 26) at screening were analyzed separately.

resultsAfter expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. The proportions of subjects with cutaneous P-SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA.

interpretationIn this prospective, blinded, cross-sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P-SYN detected in skin biopsies. Almost 1/3 of subjects with reduced MoCA testing also had P-SYN detected. These results support a role for skin biopsy detection of P-SYN in patients with DLB.

trial registrationNCT04700722.

Indexed as

alpha-SynucleinLewy Body DiseaseSkinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPhosphorylationProspective Studiesalpha-SynucleinSNCA protein, humandementia with Lewy bodiesmild cognitive impairmentskin biopsysynucleinopathy

Identifiers

PMID41449577
PMCPMC13161868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.